

Franziska Haderk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2230818/publications.pdf>

Version: 2024-02-01

22
papers

2,594
citations

840776

11
h-index

888059

17
g-index

28
all docs

28
docs citations

28
times ranked

5915
citing authors

#	ARTICLE	IF	CITATIONS
1	Obstacles and opportunities in the functional analysis of extracellular vesicle RNA – an ISEV position paper. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1286095.	12.2	561
2	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. <i>Genome Research</i> , 2013, 23, 1446-1461.	5.5	526
3	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. <i>Blood</i> , 2015, 126, 1106-1117.	1.4	399
4	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. <i>Cell</i> , 2020, 182, 1232-1251.e22.	28.9	371
5	RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. <i>Nature Cell Biology</i> , 2018, 20, 1064-1073.	10.3	276
6	Tumor-derived exosomes modulate PD-L1 expression in monocytes. <i>Science Immunology</i> , 2017, 2, .	11.9	236
7	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. <i>Current Opinion in Chemical Biology</i> , 2021, 62, 1-12.	6.1	83
8	Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. <i>Blood</i> , 2014, 124, 1968-1968.	1.4	28
9	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <i>Cancers</i> , 2017, 9, 164.	3.7	26
10	Extracellular vesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1826-1830.	1.3	15
11	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
12	Betacellulin drives therapy resistance in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 457-469.	1.2	8
13	Immunohistochemistry to Study YAP in Human Tissue Samples. <i>Methods in Molecular Biology</i> , 2019, 1893, 89-95.	0.9	6
14	Extracellular vesicles prime the bone marrow niche. <i>Blood</i> , 2021, 138, 4-6.	1.4	2
15	Chronic Lymphocytic Leukemia-Exosomes Switch Endothelial and Mesenchymal Stromal Cells into Cancer-Associated Fibroblasts to Sustain Leukemic Cell Survival. <i>Blood</i> , 2014, 124, 2927-2927.	1.4	2
16	Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. <i>Journal of Visualized Experiments</i> , 2021, . .	0.3	2
17	CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. <i>Blood</i> , 2016, 128, 3217-3217.	1.4	1
18	Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy. , 2021, . .		0

#	ARTICLE	IF	CITATIONS
19	Abstract A30: Chronic lymphocytic leukemia-derived extracellular vesicles mediate NFkB signaling and pro-inflammatory cytokine release in monocytes. , 2016, , .		0
20	Abstract 3993: Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF. , 2018, , .		0
21	Abstract PR11: Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC. , 2020, , .		0
22	B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, S27.	1.1	0